collapse Signs of sepsis: high fever or very low temperature, rapid breathing, confusion, or feeling extremely unwell following an injection Severe hypoglycaemia with loss of consciousness or inability to swallow Severe chest pain or significant difficulty breathing Contact your GP or a healthcare professional promptly if you experience: Injection site reactions such as persistent redness, swelling, warmth, or pain, which may indicate infection or an inflammatory response Systemic symptoms including fever, chills, or malaise following administration Gastrointestinal symptoms such as severe or persistent nausea, vomiting, or abdominal pain these are known effects associated with GLP-1 receptor agonism and may require clinical assessment [15] [6] Symptoms of hypoglycaemia shakiness, sweating, confusion, or palpitations particularly if retatrutide is being used alongside other glucose-lowering agents Cardiovascular symptoms such as a rapid or irregular heartbeat Report suspected side effects via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk
It is likely that the larger number of statistically significant changes to the microbiome observed in the groups switched from WD to LD reflects their more numerous exposures to different diets, longitudinal changes in dietary exposure, the stress associated with diet switch, the negative energy state achieved by treatment and/or diet-driven weight loss, or a combination of these factors, but it may also be related to differences in terminal body weight and fat mass since both adiposity and diet composition have been shown to modulate the mouse gut microbiome profile
Both define the 0.9% concentration, the pH range of 4.5 to 7.0, and the 28-day post-puncture window used here
It has a pH near 7.0, which falls within the stability range for semaglutide
